5'‑isomiR is the most abundant sequence of miR‑1246, a candidate biomarker of lung cancer, in serum

血清中 5'‐isomiR 是 miR‐1246(肺癌候选生物标志物)最丰富的序列。

阅读:10
作者:Toshiko Aiso,Makiko Ueda

Abstract

MicroRNA (miRNA/miR) 5'‑isoforms (5'‑isomiRs) differ from canonical sequences registered in the microRNA database in the length of their 5' ends. The 'seed sequence' of miRNAs that bind to target mRNAs is 2‑8 nucleotides from the 5' end; thus, shifts at the 5' end can cause a 'seed shift'. Accumulating data from miRNA deep sequencing have revealed that, in a substantial number of miRNAs, sequences corresponding to specific isomiRs, not the canonical form, are the most abundant. Studies have so far focused on circulating miRNAs as either markers or intercellular communication factors. miR‑1246 is abundant in the serum and is a candidate diagnostic and prognostic marker for esophageal squamous cell carcinoma, pancreatic cancer, hepatocellular carcinoma, colorectal adenocarcinoma and non‑small cell lung cancer (NSCLC). The present study analyzed the 5'‑end of serum miR‑1246 by fragment analysis and found that a 5'‑isomiR, which is two bases shorter than the canonical sequence, was the most abundant sequence in patients with NSCLC as well as healthy donors. To quantify the 5'‑isomiR, 5'‑isomiR‑specific primers based on primers for allele specific‑PCR were used, primarily because commercially available methods for miRNA Reverse transcription‑quantitative PCR cannot discriminate among sequences, especially those located at the 5' end of miRNA. The total miR‑1246 levels were significantly increased in patients with NSCLC; by contrast, the level of the canonical sequence was significantly decreased. Significant positive correlations were observed between the total miR‑1246 levels and the 5'‑isomiR levels, but not that of the canonical sequence. These results imply that the increase in levels of serum miR‑1246 in patients with NSCLC depends on increase of the 5'‑isomiR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。